Raftery, J.; Clegg, A.; Jones, J.; Tan, S.C.; Lotery, A. - 2007
Two new drugs provide startling benefits in the treatment of age-related macular degeneration (AMD). The clinical and cost effectiveness of ranibizumab (Lucentis) was compared to that of bevacizumab (Avastin), which costs up to 100 times less. A cost effectiveness model was developed to assess...